



GUJARAT TERCE LABORATORIES LIMITED

8 November 2025

To,
BSE Limited
(Security Code: 524314)
Phiroze Jeejeeboy Towers,
Dalal Street, Fort,
Mumbai- 400 001.

Dear Sirs,

Sub: Outcome of the Board Meeting held on 8 November 2025 – Unaudited Standalone Financial Results of the Company for the second quarter and half year ended 30 September 2025 - Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Ref: Intimation of Board Meeting vide letter dated 2 November 2025

We hereby inform you that, in compliance with Regulation 30 read with Schedule III, Regulation 33 and other applicable provisions of the SEBI Listing Regulations, the Board of Directors of Gujarat Terce Laboratories Limited ("the Company"), at their Meeting held today viz. Saturday, 8 November 2025, has inter-alia, approved Unaudited Standalone Financial Results of the Company for the second quarter and half year ended 30 September 2025, subjected to Limited Review of the Statutory Auditor of the Company.

In this regard, please find enclosed the following documents prepared in compliance with Regulations 33 and 47 (as applicable) of the SEBI Listing Regulations:

1. Unaudited Standalone Financial Results for the second quarter and half year ended 30 September 2025, Unaudited Standalone Statement of Assets and Liabilities and Cash Flow Statement as on 30 September 2025 and notes thereon;
2. Unmodified Limited Review Report on the Unaudited Standalone Financial Results for the second quarter and half year ended 30 September 2025, issued by the Company's Statutory Auditor – M.A. Shah & Co.;
3. Extract of the newspaper publication of the Unaudited Standalone Financial Results for the second quarter and half year ended 30 September 2025 in prescribed format to be published in print and electronic versions of the newspapers.

The Meeting of the Board of Directors of the Company commenced at 2:00 p.m. (IST) and concluded at 2:57 p.m. (IST).



GUJARAT TERCE LABORATORIES LIMITED

This intimation is also being uploaded on the website of the Company and can be accessed at the weblink:
<https://www.gujaratterce.in/financial-results/>

Thanking you

For Gujarat Terce Laboratories Limited

ASHKA
SOLANKI

Digitally signed
by ASHKA
SOLANKI
Date: 2025.11.08
15:01:11 +05'30'

Ms. Ashka Solanki
Company Secretary

Enclosures: As above

Regd. Office & Factory : 122/2 Ravi Estate, Bileshwarpura,
Chhatral, Ta. : Kalol, Dist. : Gandhinagar (Guj.) INDIA.
Ph.: 02764-233182 ● E.mail : gtl.factory@gmail.com

Admn. Office : D/801 & 802, The First, Behind Keshavbaug Party Plot,
Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat.(INDIA) ● Ph.: 079-48933701
E.mail : ho@gujaratterce.com ● Web. : www.gujaratterce.com

CIN:L24100GJ1985PLC007753

Limited Review Report for unaudited standalone quarterly results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

We have reviewed the accompanying statement of unaudited financial results of Gujarat Terce Laboratories Limited for the half year ended on September, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 08th November 2025

Place: Anand

For, M. A. Shah & Co.
Chartered Accountants
FRN: 0112630W



Param Doshi, FCA
(Partner)

Mem. No.: 185648

UDIN: 25185648BM00002968




GUJARAT TERCE LABORATORIES LIMITED

Statement of Unaudited Standalone Financial Results for the Quarter/Half Year Ended 30/09/2025. [Rs.in Lakhs except per share detail]						
Particulars	Quarter ended			Half Year ended		Year ended
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	Un Audited	Unaudited	Un Audited	Un Audited	Un Audited	Audited
1	2	3	4	5	6	7
I. Revenue from operations	1,292.63	1,085.36	1,330.12	2,377.99	2,519.00	5,019.52
II. Other income	5.52	9.48	8.05	15.00	15.38	30.78
III. Total Revenue (I+II)	1,298.15	1,094.84	1,338.17	2,392.99	2,534.38	5,050.30
IV. Expenses:						
a) Cost of Material consumed	129.93	198.38	145.12	328.31	475.62	914.31
b) Purchase of stock in trade	274.78	258.99	164.70	533.77	463.01	1,014.85
c) Changes in inventories of finished goods WIP and stock in trade	26.93	(15.31)	136.59	11.62	8.73	(38.14)
d) Employees benefits expenses.	416.60	374.86	421.05	791.46	804.62	1,618.93
e) Finance Costs	6.50	4.93	13.40	11.43	26.23	41.54
f) Depreciation and amortisation exp.	9.62	9.61	9.44	19.23	18.68	38.46
g) Other Expenses	255.45	270.48	296.50	525.93	593.06	1,121.31
Total Expenses	1,119.81	1,101.94	1,186.80	2,221.75	2,389.95	4,711.26
V Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV)	178.34	(7.10)	151.37	171.24	144.43	339.04
VI Exceptional items.	-	-	-	-	-	-
VII Profit/(Loss) before extraordinary items and Tax (V-VI)	178.34	(7.10)	151.37	171.24	144.43	339.04
VIII Extraordinary items	-	-	-	-	-	-
IX Profit/(Loss) before Tax (VII-VIII)	178.34	(7.10)	151.37	171.24	144.43	339.04
X Tax Expenses						
1) Current Tax	44.04	-	-	44.04	-	16.36
2) Deferred Tax	(6.06)	(2.75)	3.15	(8.81)	3.97	78.84
3) Income-Tax of Earlier Year	-	-	-	-	-	341.71
XI Profit/(Loss) for the period from continuing operations (IX-X)	140.36	(4.35)	148.22	136.01	140.46	(97.87)
XII Other Comprehensive Income						
A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII Other Comprehensive Income for the period, net of tax	-	-	-	-	-	-
XIV Total Comprehensive Income for the period (XI+XII)	140.36	(4.35)	148.22	136.01	140.46	(97.87)
XV Paid up Equity Capital (at par value of Rs. 10 each)	742.03	742.03	742.03	742.03	742.03	742.03
XVI Earning per equity share						
a) Basic	1.89	-0.06	2.00	1.83	1.89	-1.31
b) Diluted	1.80	-0.06	1.90	1.75	1.80	-1.26
(See accompanying notes to the Financial Results)						

Place: Ahmedabad

Date: 08/11/2025



For, Gujarat Terce Laboratories Limited

(Signature)

Aalap Prajapati

Managing Director & CEO

DIN: 08088327

Notes:

1	The above Unaudited Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on November 08, 2025.
2	The Limited Review Report for the quarter and half year ended on 30.09.2025 has been carried out by the statutory auditor, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.
3	The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these Unaudited financial results of the company for the quarter ended 30.09.2025 has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
4	The Company is operating in single (Pharmaceutical) segment, so above Unaudited Financial Results are for single segment only.
5	The figures of the previous quarter / periods has been regrouped/reclassified, wherever necessary.

Regd. Office & Factory: 122/2 Ravi Estate, Bileshwarpura, Chhatral, Ta.: Kalol, Dist.: Gandhinagar (Guj.) INDIA.

• **E.mail:** gtl.factory@gmail.com



• **CIN:** L24100GJ1985PLC007753

Admin. Office: D/801 & 802, The First, Near ITC Narmada, Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat. (INDIA) • **Ph.:** +91-79-35200400

• **E.mail:** ho@gujaratterce.com • **Web.:** www.gujaratterce.com



GUJARAT TERCE LABORATORIES LIMITED

Unaudited Standalone Statement of Assets and Liabilities As on 30th September, 2025			
		(Rs. In Lakhs)	
	Particulars	As at 30.09.2025	As at 31.03.2025
	1	2	3
A	ASSETS	UnAudited	Audited
1	Non-current assets		
	(a) Fixed assets		
	(i) Property, Plant & Equipment	347.32	365.39
	(ii) Capital work in Progress	-	-
	(iii) Other Intangible Assets	-	-
	(b) Financial Assets		
	(i) Investment	0.37	0.36
	(ii) Loans	157.31	215.57
	(iii) Other Financial Assets	7.69	7.69
	(c) Deferred Tax Assets(Net)	52.19	43.38
	(d) Other Non Current Assets	447.88	447.88
	Total non-current assets	1,012.76	1,080.27
2	Current assets		
	(a) Inventories	345.73	367.77
	(b) Financial Assets		
	investment	262.38	51.14
	(i) Trade receivables	635.57	506.86
	(ii) Cash and cash equivalents	36.13	77.94
	(iii) Other Bank Balances		
	(iv) Loans	17.33	17.33
	(v) Other Financial Assets	-	50.00
	(vi) Current Tax Assets (Net)	4.31	4.84
	(c) Other current assets	128.35	126.61
	Total current assets	1,429.80	1,202.49
	Total ASSETS	2,442.56	2,282.76
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	742.03	742.03
	(b) Other Equity	6.73	(129.28)
	(c) Money Received Against Share Warrants	35.00	35.00
	Total Equity	783.76	647.75
2	Liabilities		
3	Non-current liabilities		
	(a) Financial Liabilities	10.66	29.77
	(b) Deferred tax liabilities (net)		
	(c) Long-term provisions	151.70	151.70
	(d) Other Financial Liabilities	149.23	189.23
	Total non-current liabilities	311.59	370.70
4	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowing	48.67	64.41
	(ii) Trade payables		
	a Total outstanding Dues of Micro & Small enterprise	336.75	286.56
	b Total outstanding Dues of Creditors other than Micro & Small enterprise	75.07	74.86
	(iii) Other Financial Liabilities		
	(b) Short-term provisions	769.66	708.79
	(c) Other Current Liabilities	117.06	129.69
	Total current liabilities	1,347.21	1,264.31
	Total Equity and Liabilities	2,442.56	2,282.76
Place: Ahmedabad		For, Gujarat Terce Laboratories Limited	
Date: 08/11/2025		 Aalap Prajapati Managing Director & CEO DIN: 08088327	
			

Regd. Office & Factory: 122/2 Ravi Estate, Bileshwarpura, Chhatral, Ta.: Kalol, Dist.: Gandhinagar (Guj.) INDIA.

• **E.mail:** gtl.factory@gmail.com
• **CIN:** L24100GJ1985PLC007753

Admin. Office: D/801 & 802, The First, Near ITC Narmada, Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat. (INDIA) • **Ph.:** +91-79-35200400

• **E.mail:** ho@gujaratterce.com • **Web.:** www.gujaratterce.com



GUJARAT TERCE LABORATORIES LIMITED

Statement of Standalone Cash Flows for the half-year ended 30th September 2025

	PARTICULARS	30th September 2025	30th September 2024
		Unaudited	Unaudited
A. Cash Flow from Operating Activities			
Net Profit before tax (as per Statement of Profit and Loss)		171.24	144.43
Adjustments for non-cash/non-trade items:			
Depreciation & Amortization Expenses		19.23	18.68
Finance Costs		11.43	23.35
Interest received		(15.00)	(12.33)
Operating profits before Working Capital Changes		186.90	174.13
Adjusted For:			
(Increase)/Decrease in trade receivables		(128.71)	(223.58)
Increase/(Decrease) in trade payables		50.40	(193.81)
(Increase)/Decrease in inventories		22.04	22.46
Increase/(Decrease) in other current liabilities		(12.63)	17.27
Increase/(Decrease) in short term loans & advances		(50.00)	(0.50)
(Increase)/Decrease in other current assets		(10.55)	(7.16)
Cash generated from Operations		57.45	(211.19)
Income tax paid		43.61	(4.31)
Net Cash flow from Operating Activities (A)		101.06	(215.50)
B. Cash Flow from Investing Activities			
Purchase of tangible assets		1.38	(17.14)
Purchase/(Sale) of non-current investments		0.01	26.94
Interest Received		15.00	12.33
Cash advances and loans made to other parties		(211.24)	(2.50)
Cash advances and loans received back		58.26	0.88
Other inflows of cash		-	2.77
Net Cash used in Investing Activities (B)		(136.59)	23.28
C. Cash Flow from Financing Activities			
Finance Cost		(11.43)	(23.35)
Increase in/(Repayment of) Short-term Borrowings		(15.74)	68.52
Increase in/(Repayment of) Long-term borrowings		(19.11)	(37.48)
Proceeds from issue of share warrants		-	35.00
Other cash flows from financing activities		40.00	150.00
Net Cash used in Financing Activities (C)		(6.28)	192.69
D. Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)		(41.81)	0.47
E. Cash & Cash Equivalents at Beginning of period		77.94	9.01
F. Cash & Cash Equivalents at End of period		36.13	9.48
G. Net Increase/(Decrease) in Cash & Cash Equivalents (F-E)		(41.81)	0.47
Place: Ahmedabad		For, Gujarat Terce Laboratories Limited  Aalap Prajapati Managing Director & CEO DIN: 08088327	
Date: 08/11/2025			

Note: The above Cash Flow Statement has been prepared as per 'Indirect Method' as set out in Ind AS 7, Statement of Cash Flows.